A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

  • STATUS
    Recruiting
  • End date
    Dec 22, 2022
  • participants needed
    2055
  • sponsor
    GlaxoSmithKline
Updated on 1 March 2021
nitrite
gepotidacin
dysuria
cystitis
nitrofurantoin
acute cystitis
leukocyte esterase

Summary

This study will be conducted to evaluate the therapeutic response of oral gepotidacin compared to oral nitrofurantoin for uncomplicated UTI in adolescent and adult female subjects. In this study, subjects will be randomly assigned in a 1:1 ratio to receive either oral gepotidacin or oral nitrofurantoin. The study will enroll approximately 2000 subjects with uncomplicated UTI. The duration of the study will be approximately 28 days.

Details
Condition Bacterial Infection, Urinary tract infection, Recurrent Urinary Tract Infection, Recurrent Urinary Tract Infections, Urinary Tract Infections, Bacterial Infections, urinary tract infection (uti), urinary infection, recurrent utis
Treatment Nitrofurantoin, Gepotidacin, Placebo matching nitrofurantoin, Placebo matching gepotidacin
Clinical Study IdentifierNCT04020341
SponsorGlaxoSmithKline
Last Modified on1 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 12 yrs?
Are you female?
Do you have any of these conditions: Urinary tract infection or Bacterial Infection or Urinary Tract Infections or Bacterial Infections?
Do you have any of these conditions: Recurrent Urinary Tract Infection or Bacterial Infections or Recurrent Urinary Tract Infections or urinary tract infection (uti) or recurrent utis or ...?
Do you have any of these conditions: Bacterial Infection or Urinary tract infection or Recurrent Urinary Tract Infection or urinary infection or Urinary Tract Infections or Bacterial Infe...?
Do you have any of these conditions: urinary tract infection (uti) or Urinary tract infection or Bacterial Infection or urinary infection or Urinary Tract Infections or Recurrent Urinary ...?
Do you have any of these conditions: Recurrent Urinary Tract Infections or Urinary tract infection or urinary infection or urinary tract infection (uti) or recurrent utis or Bacterial Inf...?
Do you have any of these conditions: Urinary tract infection or urinary tract infection (uti) or urinary infection or Recurrent Urinary Tract Infection or Bacterial Infections or Recurren...?
Do you have any of these conditions: Bacterial Infections or Urinary tract infection or Bacterial Infection or urinary infection or Recurrent Urinary Tract Infection or urinary tract infe...?
Do you have any of these conditions: urinary tract infection (uti) or Recurrent Urinary Tract Infections or recurrent utis or urinary infection or Bacterial Infections or Bacterial Infect...?
Do you have any of these conditions: urinary tract infection (uti) or recurrent utis or Urinary Tract Infections or Recurrent Urinary Tract Infections or urinary infection or Bacterial In...?
Subjects having >=12 years of age at the time of signing the informed consent
Subjects having body weight of >45 kilogram (kg)
Subjects having 2 or more of the following clinical signs and symptoms of acute cystitis with onset <=72 hours prior to study entry: dysuria, frequency, urgency, or lower abdominal pain
Subjects having nitrite or pyuria (>15 white blood cells [WBC]/ high power field [HPF] or the presence of 3+/moderate leukocyte esterase) from a pretreatment clean-catch midstream urine sample based on local laboratory procedures
Female subjects are included
Female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or A WOCBP who agrees to follow the contraceptive guidance (to abstain from sexual activity to prevent possible re-infection) from the Baseline Visit through completion of the TOC Visit
Subject is capable of giving signed informed consent/assent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)/assent form and in this protocol

Exclusion Criteria

Subjects reside in a nursing home or dependent care type-facility
Subject has a body mass index >=40.0 kilogram per square meter (kg/m^2) or a body mass index >=35.0 kg/m^2 and is experiencing obesity-related health conditions such as high blood pressure or uncontrolled diabetes
Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates her participation
Subject is immunocompromised or has altered immune defenses that may predispose the subject to a higher risk of treatment failure and/or complications. For example, uncontrolled diabetes, renal transplant recipients, subjects with clinically significant persistent granulocytopenia (absolute neutrophil count <1000 per microliter [L]), and subjects receiving immunosuppressive therapy, including corticosteroid therapy [>40 mg per day prednisolone or equivalent for >1 week, >=20 mg per day prednisolone or equivalent for >2 weeks, or prednisolone or equivalent >=10 mg per day for >6 weeks]). Subjects with a known cluster of differentiation 4 (CD4) count of <200 cells per cubic millimeter (cells/mm^3) should not be enrolled
Subject has a medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as, Poorly controlled asthma or chronic obstructive pulmonary disease at Baseline and, in the opinion of the investigator, not stable on current therapy or acute severe pain, uncontrolled with conventional medical management or active peptic ulcer disease or parkinson disease or myasthenia gravis or a history of seizure disorder requiring medications for control (this does not include a history of childhood febrile seizures) or subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study treatment (For example, ileostomy or malabsorption syndrome)
Subject has a known glucose-6-phosphate dehydrogenase deficiency
Subject, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up
Subject has a serious underlying disease that could be imminently life-threatening, or the subject is unlikely to survive for the duration of the study period
Subject has acute cystitis that is known or suspected to be due to fungal, parasitic, or viral pathogens; or known or suspected to be due to Pseudomonas aeruginosa or Enterobacteriaceae (other than E. coli) as the contributing pathogen
Subject has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis, that may interfere with the clinical efficacy assessments
Subject has an anatomical or physiological anomaly that predisposes the subject to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction or stricture of the urinary tract, primary renal disease (for example, polycystic renal disease), or neurogenic bladder, or the subject has a history of anatomical or functional abnormalities of the urinary tract (for example, chronic vesico-ureteral reflux, detrusor insufficiency)
Subject has an indwelling catheter, nephrostomy, ureter stent, or other foreign material in the urinary tract
Subject who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (for example, pyelonephritis, urosepsis), signs and symptom onset >=96 hours before study entry, or a temperature >=101 Degrees Fahrenheit (F), flank pain, chills, or any other manifestations suggestive of upper UTI
Subject has known anuria, oliguria, or significant impairment of renal function (creatinine clearance <60 mL/min or clinically significant elevated serum creatinine as determined by the investigator)
Subject presents with vaginal discharge at Baseline, for example, suspected sexually transmitted disease
Subject has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval
Subject has uncompensated heart failure
Subject has severe left ventricular hypertrophy
Subject has a family history of QT prolongation or sudden death
Subject has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady-arrhythmia within the last 12 months
Subject is taking QT-prolonging drugs or drugs known to increase the risk of torsades de pointes (TdP) per the [www.crediblemeds.org](http://www.crediblemeds.org/). "Known Risk of TdP" category at the time of her Baseline Visit, which cannot be safely discontinued from the Baseline Visit to the TOC Visit; or the subject is taking a strong cytochrome P450 enzyme 3A4 (CYP3A4) inhibitor or a strong P-glycoprotein (P-gp) inhibitor
For any subject >=12 to <18 years of age, the subject has an abnormal electrocardiogram (ECG) reading
Subject has a QTc >450 millisecond (msec) or a QTc >480 msec for subjects with bundle-branch block
Subject has a documented or recent history of uncorrected hypokalemia within the past 3 months
Subject has a known alanine aminotransferase (ALT) value >2 times upper limit of normal (ULN)
Subject has a known bilirubin value >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
Subject has a current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), including symptomatic viral hepatitis or moderate-to-severe liver insufficiency (Child Pugh class B or C)
Subject has a previous history of cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin
Subject has received treatment with other systemic antimicrobials or systemic antifungals within 1 week before study entry
Subject must agree not to use the medications or nondrug therapies from the Baseline Visit through the TOC Visit
Subject has been previously enrolled in this study or has previously been treated with gepotidacin
Subject has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives, whichever is longer
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note